These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32841782)

  • 21. Analysis of Tau-441 protein in clinical samples using rGO/AuNP nanocomposite-supported disposable impedimetric neuro-biosensing platform: Towards Alzheimer's disease detection.
    Sonuç Karaboga MN; Sezgintürk MK
    Talanta; 2020 Nov; 219():121257. PubMed ID: 32887148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aptamer-Functionalized Carbon Nanotube Field-Effect Transistor Biosensors for Alzheimer's Disease Serum Biomarker Detection.
    Chen H; Xiao M; He J; Zhang Y; Liang Y; Liu H; Zhang Z
    ACS Sens; 2022 Jul; 7(7):2075-2083. PubMed ID: 35816677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting.
    Jung NY; Kim ES; Kim HS; Jeon S; Lee MJ; Pak K; Lee JH; Lee YM; Lee K; Shin JH; Ko JK; Lee JM; Yoon JA; Hwang C; Choi KU; Lee EC; Seong JK; Huh GY; Kim DS; Kim EJ
    J Alzheimers Dis; 2020; 74(2):473-490. PubMed ID: 32039853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium.
    Somers C; Struyfs H; Goossens J; Niemantsverdriet E; Luyckx J; De Roeck N; De Roeck E; De Vil B; Cras P; Martin JJ; De Deyn PP; Bjerke M; Engelborghs S
    J Alzheimers Dis; 2016 Aug; 54(1):383-95. PubMed ID: 27567807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.
    Kang JH; Korecka M; Figurski MJ; Toledo JB; Blennow K; Zetterberg H; Waligorska T; Brylska M; Fields L; Shah N; Soares H; Dean RA; Vanderstichele H; Petersen RC; Aisen PS; Saykin AJ; Weiner MW; Trojanowski JQ; Shaw LM;
    Alzheimers Dement; 2015 Jul; 11(7):772-91. PubMed ID: 26194312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Highly sensitive quantification of Alzheimer's disease biomarkers by aptamer-assisted amplification.
    Chan HN; Xu D; Ho SL; He D; Wong MS; Li HW
    Theranostics; 2019; 9(10):2939-2949. PubMed ID: 31244934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selecting Aβ isoforms for an Alzheimer's disease cerebrospinal fluid biomarker panel.
    Somers C; Goossens J; Engelborghs S; Bjerke M
    Biomark Med; 2017 Feb; 11(2):169-178. PubMed ID: 28111962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
    Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
    J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Temporal association patterns and dynamics of amyloid-β and tau in Alzheimer's disease.
    Ower AK; Hadjichrysanthou C; Gras L; Goudsmit J; Anderson RM; de Wolf F;
    Eur J Epidemiol; 2018 Jul; 33(7):657-666. PubMed ID: 29071500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frontal variant of Alzheimer's disease with asymmetric presentation mimicking frontotemporal dementia: Case report and literature review.
    Li CH; Fan SP; Chen TF; Chiu MJ; Yen RF; Lin CH
    Brain Behav; 2020 Mar; 10(3):e01548. PubMed ID: 31989779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease.
    Lista S; Garaci FG; Ewers M; Teipel S; Zetterberg H; Blennow K; Hampel H
    Alzheimers Dement; 2014 May; 10(3):381-92. PubMed ID: 23850330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current trends in blood biomarker detection and imaging for Alzheimer's disease.
    Hu S; Yang C; Luo H
    Biosens Bioelectron; 2022 Aug; 210():114278. PubMed ID: 35460969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biosensing: The best alternative for conventional methods in detection of Alzheimer's disease biomarkers.
    Mobed A; Hasanzadeh M
    Int J Biol Macromol; 2020 Oct; 161():59-71. PubMed ID: 32504710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.
    Hampel H; Mitchell A; Blennow K; Frank RA; Brettschneider S; Weller L; Möller HJ
    J Neural Transm (Vienna); 2004 Mar; 111(3):247-72. PubMed ID: 14991453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Two Analytical Platforms in Cerebrospinal Fluid Biomarkers for the Classification of Alzheimer's Disease Spectrum with Amyloid PET Imaging.
    Lim HJ; Park JE; Kim BC; Choi SM; Song MK; Cho SH; Seo HJ; Kim J; Song HC; Choi KY; Lee JJ; Kim HW; Ha JM; Song WK; Park SG; Lee JS; Lee KH
    J Alzheimers Dis; 2020; 75(3):949-958. PubMed ID: 32390627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hybrid Graphene Oxide Based Plasmonic-Magnetic Multifunctional Nanoplatform for Selective Separation and Label-Free Identification of Alzheimer's Disease Biomarkers.
    Demeritte T; Nellore BP; Kanchanapally R; Sinha SS; Pramanik A; Chavva SR; Ray PC
    ACS Appl Mater Interfaces; 2015 Jun; 7(24):13693-700. PubMed ID: 26027901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ratio Aβ1-42:p-Tau: a Possible Diagnostic Tool in Differentiating Dementias.
    De Riva V; Galloni E; Lealini B; Zarantonello G; Disco C; Dionisio LD; Meligrana L; Marcon M; Perini F
    Clin Lab; 2019 May; 65(5):. PubMed ID: 31115229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
    Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A
    J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.